{"pmid":32367645,"title":"Response to \"The COVID-19 outbreak in Italy: initial implications for organ transplantation programs\".","text":["Response to \"The COVID-19 outbreak in Italy: initial implications for organ transplantation programs\".","I read the article on the overall reduction of Solid Organ Transplantation (SOT) activity in Italy, with growing concerns as also the National Regulatory Bodies (NRB) of Spain and the UK report substantial reduction of activity in their bulletins; currently, in the UK only five Kidney TxC are still operational. Importantly, another study reported in the US restricted SOT, with more than 70% of US Transplant Centres (TxC) having suspended Living Donor Kidney Transplantation (LDKT).","Am J Transplant","Cacciola, Roberto","32367645"],"abstract":["I read the article on the overall reduction of Solid Organ Transplantation (SOT) activity in Italy, with growing concerns as also the National Regulatory Bodies (NRB) of Spain and the UK report substantial reduction of activity in their bulletins; currently, in the UK only five Kidney TxC are still operational. Importantly, another study reported in the US restricted SOT, with more than 70% of US Transplant Centres (TxC) having suspended Living Donor Kidney Transplantation (LDKT)."],"journal":"Am J Transplant","authors":["Cacciola, Roberto"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367645","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/ajt.15968","locations":["Italy","Spain","GBR","GBR","US","Italy"],"countries":["United States","Italy","United Kingdom","Spain"],"countries_codes":["USA|United States","ITA|Italy","GBR|United Kingdom","ESP|Spain"],"weight":0,"_version_":1666138496293666816,"score":9.490897,"similar":[{"pmid":32282982,"title":"Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","text":["Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.","COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices.","Am J Transplant","Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M","32282982"],"abstract":["COVID-19 is a novel, rapidly-changing pandemic: consequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the US, and center-level variation in testing, clinical practice, and policies, we conducted a national survey between March 24-31, 2020 and linked responses to the COVID-19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID-19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID-19. Shortage of COVID-19 tests was reported by 42.5%. Respondents reported a total of 148 COVID-19 recipients from <1y to >10y post-transplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center-level response across the US; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence-based practices."],"journal":"Am J Transplant","authors":["Boyarsky, Brian J","Chiang, Teresa Po-Yu","Werbel, William A","Durand, Christine M","Avery, Robin K","Getsin, Samantha N","Jackson, Kyle R","Kernodle, Amber B","Van Pilsum Rasmussen, Sarah E","Massie, Allan B","Segev, Dorry L","Garonzik-Wang, Jacqueline M"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282982","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15915","keywords":["clinical decision-making","epidemiology","guidelines","infectious agents - viral"],"locations":["US","US","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","tocilizumab","Azithromycin"],"topics":["Prevention"],"weight":1,"_version_":1666138491535228928,"score":172.20128},{"pmid":32460390,"title":"Covid-19 in solid organ transplant recipients: A single center experience.","text":["Covid-19 in solid organ transplant recipients: A single center experience.","BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID-19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney-after-heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non-immunocompromised patients Eighty-three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti-viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19.","Transpl Int","Hoek, Rogier A S","Manintveld, Olivier C","Betjes, Michiel G H","Hellemons, Merel E","Seghers, Leonard","van Kampen, Jeroen A A","Caliskan, Kadir","van de Wetering, Jacqueline","van den Hoogen, Martijn","Metselaar, Herold J","Hesselink, Dennis A","32460390"],"abstract":["BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID-19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney-after-heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non-immunocompromised patients Eighty-three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti-viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19."],"journal":"Transpl Int","authors":["Hoek, Rogier A S","Manintveld, Olivier C","Betjes, Michiel G H","Hellemons, Merel E","Seghers, Leonard","van Kampen, Jeroen A A","Caliskan, Kadir","van de Wetering, Jacqueline","van den Hoogen, Martijn","Metselaar, Herold J","Hesselink, Dennis A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460390","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/tri.13662","keywords":["covid-19","sars-cov-2","organ transplantation","solid organ transplantation"],"topics":["Treatment"],"weight":1,"_version_":1667967698947014659,"score":164.14812},{"pmid":32243677,"title":"The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs.","text":["The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs.","The spread of Coronavirus Disease 2019 (COVID-19) has already reached a pandemic dimension within a few weeks. Italy has been one of the first countries dealing with the outbreak of COVID-19, and severe measures have been adopted to limit viral transmission. The spread of COVID-19 may have several implications in organ transplant activity that physicians should be aware of. The initial experience gained during the COVID-19 outbreak shows that around 10% of infected patients in Italy need intensive care management to overcome the acute respiratory distress syndrome. Due to the exponential rise of infected patients we are now facing an actual risk of saturation of intensive care unit (ICU) beds. A restriction in the number of ICU beds available for both donors and transplant recipients may unfavorably influence the overall donation activity, and eventually lead to a reduced number of transplants. Preliminary Italian data show that a 25% reduction of procured organs has already occurred during the first 4 weeks of COVID-19 outbreak. This underlines the need to closely monitor what will be further happening in ICUs due to the COVID-19 spread in the attempt to preserve transplant activity, especially in Western countries where deceased donors represent the major organ resource.","Am J Transplant","Angelico, Roberta","Trapani, Silvia","Manzia, Tommaso Maria","Lombardini, Letizia","Tisone, Giuseppe","Cardillo, Massimo","32243677"],"abstract":["The spread of Coronavirus Disease 2019 (COVID-19) has already reached a pandemic dimension within a few weeks. Italy has been one of the first countries dealing with the outbreak of COVID-19, and severe measures have been adopted to limit viral transmission. The spread of COVID-19 may have several implications in organ transplant activity that physicians should be aware of. The initial experience gained during the COVID-19 outbreak shows that around 10% of infected patients in Italy need intensive care management to overcome the acute respiratory distress syndrome. Due to the exponential rise of infected patients we are now facing an actual risk of saturation of intensive care unit (ICU) beds. A restriction in the number of ICU beds available for both donors and transplant recipients may unfavorably influence the overall donation activity, and eventually lead to a reduced number of transplants. Preliminary Italian data show that a 25% reduction of procured organs has already occurred during the first 4 weeks of COVID-19 outbreak. This underlines the need to closely monitor what will be further happening in ICUs due to the COVID-19 spread in the attempt to preserve transplant activity, especially in Western countries where deceased donors represent the major organ resource."],"journal":"Am J Transplant","authors":["Angelico, Roberta","Trapani, Silvia","Manzia, Tommaso Maria","Lombardini, Letizia","Tisone, Giuseppe","Cardillo, Massimo"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243677","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1111/ajt.15904","keywords":["critical care/intensive care management","donors and donation: donor-derived infections","editorial/personal viewpoint","epidemiology","health services and outcomes research","infection and infectious agents - viral","infectious disease","organ procurement and allocation","organ procurement organization","organ transplantation in general"],"locations":["Italy","Italy","Italian","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138492107751424,"score":162.07774},{"pmid":32476258,"title":"Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.","text":["Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States.","The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among ten SOT patients, including the clinical presentation, treatment modalities, and outcomes of seven renal transplant recipients, one liver transplant recipient, one heart transplant recipient, and one lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all seven hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.","Am J Transplant","Fung, Monica","Chiu, Charles Y","DeVoe, Catherine","Doernberg, Sarah B","Schwartz, Brian S","Langelier, Charles","Henrich, Timothy J","Yokoe, Deborah","Davis, John","Hays, Steven R","Chandran, Sindhu","Kukreja, Jasleen","Ng, Dianna","Prostko, John","Taylor, Russell","Reyes, Kevin","Bainbridge, Emma","Bond, Allison","Chin-Hong, Peter","Babik, Jennifer M","32476258"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among ten SOT patients, including the clinical presentation, treatment modalities, and outcomes of seven renal transplant recipients, one liver transplant recipient, one heart transplant recipient, and one lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all seven hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community."],"journal":"Am J Transplant","authors":["Fung, Monica","Chiu, Charles Y","DeVoe, Catherine","Doernberg, Sarah B","Schwartz, Brian S","Langelier, Charles","Henrich, Timothy J","Yokoe, Deborah","Davis, John","Hays, Steven R","Chandran, Sindhu","Kukreja, Jasleen","Ng, Dianna","Prostko, John","Taylor, Russell","Reyes, Kevin","Bainbridge, Emma","Bond, Allison","Chin-Hong, Peter","Babik, Jennifer M"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476258","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/ajt.16079","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Case Report"],"weight":1,"_version_":1668437834963353600,"score":157.41016},{"pmid":32412159,"title":"First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","text":["First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.","Am J Transplant","Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C","32412159"],"abstract":["Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts."],"journal":"Am J Transplant","authors":["Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412159","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.16062","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666897319106183168,"score":157.05846}]}